Nasdaq · Biotech stocks database

MSLE — Satellos Bioscience Inc.

MSLE (Satellos Bioscience Inc.) stock: $9.32, $197.7M market cap, $9.8M cash, $187.9M EV, $194.1M fully diluted market cap. Next expected readout: Mar-27. Lead program: SAT-3247 (Duchenne Muscular Dystrophy), Phase 2. Data from Fully Diluted's biotech stocks database.

Share price

$9.32

Market cap

$197.7M

Cash

$9.8M

Enterprise value

$187.9M

Balance sheet

Cash	$9.8M
Debt	$0.0M
Net cash	$9.8M
Enterprise value	$187.9M
Basic shares	21.2M shares
Fully diluted shares	20.8M shares
Fully diluted market cap	$194.1M
Cash per share	$0.46

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading MSLE daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 11 - Nov 22	SAT-3247	Phase 2	Duchenne Muscular Dystrophy (DMD)	Q4 2026
May 12 - Jun 23	SAT-3247	Phase 2	Duchenne Muscular Dystrophy; Duchenne; DMD	Q4 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	SAT-3247
Lead indication	Duchenne Muscular Dystrophy
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07287189	Phase 2	Recruiting	Sponsor	MSLE	—	Duchenne Muscular Dystrophy; Duchenne; DMD	Q4 2026
NCT06867107	Phase 2	Enrolling by invitation	Sponsor	MSLE	—	Duchenne Muscular Dystrophy (DMD)	Q4 2026

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Satellos Bioscience, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	652,590	+163,383	0.73%	2026-08-14
ADAR1 Capital Management	222,555	no change	0.08%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego